Target intelligence / Profile preview

Lysosomal cysteine protease

Molecular classification
Enzyme, Protease, Lysosomal protease
01

Overview

Lysosomal cysteine proteases are a family of papain-like enzymes found within the lysosomes of virtually all eukaryotic cells[3][5][8]. Their main function is the degradation of intracellular and endocytosed proteins within the acidic environment of the lysosome[3][5]. Prominent members include Cathepsins B, L, S, K, and H, each with distinct substrate and tissue localizations but often overlapping biological functions[1][2][3]. They are synthesized as zymogens and activated by proteolytic cleavage in acidic compartments[3][5]. Lysosomal cysteine proteases play key roles in antigen processing/presentation, bone remodeling, apoptosis, ECM turnover, and innate immunity[2][6][7]. Dysregulation or overexpression is associated with diseases such as cancer, cardiovascular disease, inflammatory disorders, osteoporosis, neurodegeneration, and various infections[4][7]. They are validated drug targets, but therapeutic intervention faces safety and selectivity challenges due to their redundancy and essential physiological roles[2][5][6].

Other names
Cathepsins (Cathepsin B, Cathepsin L, Cathepsin S, Cathepsin K, Cathepsin H, etc.)
02

Mechanism of action

Inhibition of proteolytic enzymatic activity Blockade of antigen processing (via cathepsin S inhibition) Reduced extracellular matrix degradation (e.g., in atherosclerosis or osteoporosis)

03

Biological functions

Protein degradationAntigen processing and presentationApoptosisTissue remodelingImmune response
04

Disease associations

CancerCardiovascular disease (e.g., atherosclerosis)Inflammatory diseaseAutoimmune diseaseInfectious diseaseOsteoporosisNeurodegenerative disease
05

Safety considerations

Off-target effects due to cathepsin family redundancy and broad tissue distributionPotential immune dysfunction from impaired antigen processingAdverse effects on bone metabolism (e.g., with cathepsin K inhibitors)Insufficient selectivity, resulting in toxicity when inhibiting multiple proteases
06

Interacting drugs

Cysteine protease inhibitors (E-64, leupeptin)

3 more in the full profile.

07

Biomarkers

Cathepsin S, K, B, L levels in tissue or plasmaCystatin C (endogenous inhibitor)

Beyond the preview

Go deeper on Lysosomal cysteine protease.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysosomal cysteine protease.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call